Ranibizumab Biosimilar Shows Equivalent Efficacy to Branded Drug for Neovascular AMD Ranibizumab Biosimilar Shows Equivalent Efficacy to Branded Drug for Neovascular AMD
In a phase 3 study, the ranibizumab biosimilar SB11 demonstrated equivalent efficacy and similar safety and immunogenicity profiles compared with ranibizumab for patients with neovascular age-related macular degeneration (nAMD).Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Ophthalmology News Source Type: news
More News: Age-Related Macular Degeneration (AMD) | Health | Lucentis | Opthalmology | Ranibizumab Injection | Study